TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(TEVA)
  Report
Delayed Nyse  -  05/20 04:00:02 pm EDT
8.470 USD   +1.93%
05/20Immuneering Announces Participation in Upcoming Investor Conferences
AQ
05/19INSIDER SELL : Teva Pharmaceutical Industries
MT
05/18Teva Announces New Findings Highlighting Potential of ProAir Digihaler (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 10 70210 5768 8359 405--
Enterprise Value (EV)1 35 63434 31829 71328 29225 91023 387
P/E ratio -10,8x-2,65x21,1x12,0x6,42x3,62x
Yield ------
Capitalization / Revenue 0,63x0,63x0,56x0,60x0,59x0,58x
EV / Revenue 2,11x2,06x1,87x1,81x1,62x1,43x
EV / EBITDA 7,61x6,99x6,05x5,84x5,29x4,53x
Price to Book 0,77x1,05x0,86x0,83x0,72x0,62x
Nbr of stocks (in thousands) 1 092 0891 095 9721 103 0071 110 352--
Reference price (USD) 9,809,658,018,478,478,47
Announcement Date 02/12/202002/10/202102/09/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 16 88716 65915 87815 67215 97616 300
EBITDA1 4 6854 9124 9114 8424 9015 161
Operating profit (EBIT)1 4 1424 3884 4014 3684 4434 616
Operating Margin 24,5%26,3%27,7%27,9%27,8%28,3%
Pre-Tax Profit (EBT)1 -1 265-4 406658-8031 349-
Net income1 -999-3 9904171 3181 8722 618
Net margin -5,92%-24,0%2,63%8,41%11,7%16,1%
EPS2 -0,91-3,640,380,711,322,34
Dividend per Share2 ------
Announcement Date 02/12/202002/10/202102/09/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 3 8874 1003 6613 7824 0104 241
EBITDA1 1 1701 3731 1351 1351 2611 377
Operating profit (EBIT)1 1 0421 2481 0131 0061 1181 249
Operating Margin 26,8%30,4%27,7%26,6%27,9%29,5%
Pre-Tax Profit (EBT)1 --175-971393-1 539430
Net income1 292-159-955367555675
Net margin 7,51%-3,88%-26,1%9,70%13,8%15,9%
EPS2 0,26-0,14-0,860,270,530,66
Dividend per Share ------
Announcement Date 10/27/202102/09/202205/03/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 24 93223 74220 87818 88716 50613 983
Net Cash position1 ------
Leverage (Debt / EBITDA) 5,32x4,83x4,25x3,90x3,37x2,71x
Free Cash Flow1 2 0536382362 5462 7953 067
ROE (Net Profit / Equities) 18,3%11,8%28,1%24,7%23,4%22,4%
Shareholders' equity1 -5 453-33 8351 4835 3367 99711 684
ROA (Net Profit / Asset) 4,45%5,24%5,81%5,72%5,97%6,09%
Assets1 -22 466-76 2127 17923 03831 36243 011
Book Value Per Share2 12,89,169,3210,211,813,8
Cash Flow per Share2 0,691,110,720,361,682,41
Capex1 525578562596614599
Capex / Sales 3,11%3,47%3,54%3,80%3,84%3,67%
Announcement Date 02/12/202002/10/202102/09/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 9 404 684 802
Net sales (USD) 15 878 000 000
Number of employees 35 346
Sales / Employee (USD) 449 216
Free-Float 90,0%
Free-Float capitalization (USD) 8 467 687 460
Avg. Exchange 20 sessions (USD) 90 951 079
Average Daily Capital Traded 0,97%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA